Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure.

Abstract

The VICTORIA trial demonstrated that vericiguat, a novel oral soluble guanylate cyclase stimulator, improved mortality and morbidity in patients with systolic heart failure, receiving conventional anti-heart failure medications. However, the clinical implication of vericiguat for those receiving guideline-directed medical therapy including sodium-glucose cotransporter 2 inhibitors: fantastic four, remains unknown. We had a patient with systolic heart failure, whose heart failure symptoms improved as well as cardiac reverse remodeling following 3-month vericugat therapy upon fantastic four medical therapy. Vericiguat might have an additional effect on patients receiving fantastic four medical therapy, although further studies are warranted to validate and establish our hypothesis.

Learning objective:

Clinical implication of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with systolic heart failure receiving "fantastic four" including sodium-glucose cotransporter 2 inhibitors remains uncertain. Vericiguat might have an additional effect on patients receiving fantastic four medical therapy.

• Authors: Teruhiko Imamura, Koichiro Kinugawa
• Journal: Journal of cardiology cases (J Cardiol Cases) Vol. 26 Issue 6 Pg. 429-431 (Dec 2022) ISSN: 1878-5409 [Electronic] Japan
• PMID: 36506497 (Publication Type: Case Reports)
• Copyright: © 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. All rights reserved.